Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Gamal Shiha, Gamal Esmat, Mohamed Hassany, Reham Soliman, Mohamed Elbasiony, Rabab Fouad, Aisha Elsharkawy, Radi Hammad, Wael Abdel-Razek, Talaat Zakareya, Kathryn Kersey, Benedetta Masetto, Anu Osinusi, Sophia Lu, Diana M Brainard, John G McHutchison, Imam Waked, Wahid Doss

ABSTRACT

Objective: We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens.

Design: In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 weeks of ledipasvir/sofosbuvir-ribavirin. Interferon treatment-experienced patients were randomised to receive 12 weeks of ledipasvir/sofosbuvir-ribavirin, while sofosbuvir-experienced or ledipasvir/sofosbuvir-experienced patients received 12 weeks of ledipasvir/sofosbuvir-ribavirin. Randomisation was stratified by cirrhosis status.

Results: We enrolled 255 patients from four centres in Egypt. Among treatment-naive patients, SVR12 rates were 95% and 90% for those receiving 8 weeks of ledipasvir/sofosbuvir alone and with ribavirin, respectively, and 98% for those receiving 12 weeks of ledipasvir/sofosbuvir both alone and with ribavirin. Among interferon-experienced patients, SVR rates were 94% for those receiving 12 weeks of ledipasvir/sofosbuvir and 100% for those receiving 12 weeks of ledipasvir/sofosbuvir plus ribavirin. All patients previously treated with sofosbuvir regimens who received ledipasvir/sofosbuvir plus ribavirin achieved SVR12. The most common adverse events, headache and fatigue, were more common among patients receiving ribavirin.

Conclusion: Among non-cirrhotic treatment-naive patients with HCV genotype 4, 8 weeks of ledipasvir/sofosbuvir-ribavirin was highly effective. Twelve weeks of ledipasvir/sofosbuvir-ribavirin was highly effective regardless of presence of cirrhosis or prior treatment experience, including previous treatment with sofosbuvir or ledipasvir/sofosbuvir.

Trial registration number: NCT02487030.
INTRODUCTION
In 2014, WHO issued its first viral hepatitis guidelines calling for the elimination of hepatitis C virus (HCV) infection by 2030. In line with this goal, the estimated seroprevalence of HCV in Egypt has declined from 12.5% in 2008 to 6.3% in 2015.1,2 Although the prevalence of HCV may be decreasing overall, Egypt has among the highest incidences of HCV infection worldwide with an estimated 168,600 new cases in 2013.3,4 More than 90% of Egyptian patients with HCV infections are infected by the genotype 4 strain of the virus.5,6

At the time this study was designed, the only direct-acting antiviral drug approved in Egypt was sofosbuvir. As such, the only treatment options were sofosbuvir plus ribavirin or pegylated interferon for 12 weeks or sofosbuvir plus ribavirin for 24 weeks.7 Retreatment options for patients who had failed prior direct-acting antiviral treatment were unavailable at the time. Ribavirin-free treatment options are especially crucial in patient populations for whom treatment with ribavirin is not advisable, such as older patients with underlying comorbidities. Ribavirin-free regimens are also desirable to avoid the significant side effects associated with its use, including anaemia and fatigue, as well as genotoxicity and teratogenicity.8,9

The fixed-dose combination of ledipasvir, an NS5A inhibitor, and sofosbuvir (ledipasvir–sofosbuvir) for 8 or 12 weeks has proven to be highly effective and well tolerated in patients with HCV genotype 1 in phase III studies, with rates of sustained virological response at 12 weeks post-treatment (SVR12) of 94%–99%.10–13 Data for HCV genotype 4 infection are more limited. Two phase II trials have been published in patients with HCV genotype 4 who received 12 weeks of ledipasvir–sofosbuvir. Overall SVR12 rates of 93%–95% were observed, with slightly lower rates for interferon-experienced patients (91%)13,14

We conducted this phase III study to evaluate the safety and efficacy of ledipasvir–sofosbuvir with and without ribavirin for 8 or 12 weeks in Egyptian patients with HCV genotype 4, including those with cirrhosis and those who had previously failed treatment with an interferon or sofosbuvir-based regimen.

METHODS
Study design and patients
This multicentre, randomised, open-label, phase III study enrolled adults (≥18 years) with chronic HCV genotype 4 infection. At screening, treatment-naive or interferon-experienced patients had plasma HCV RNA levels of at least 10^4 IU/mL sofosbuvir-experienced or ledipasvir–sofosbuvir-experienced patients had HCV RNA levels greater than the lower limit of quantitation (LLOQ), or 15 IU/mL. Patients with or without compensated cirrhosis were eligible. Patients with hepatic decompensation, coinfection with hepatitis B virus or HIV, or contraindications to ribavirin therapy were excluded. Detailed inclusion/exclusion criteria are presented in the online supplementary appendix.

Patients were enrolled in three cohorts. Treatment-naive patients (cohort 1) were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups: ledipasvir–sofosbuvir for 8 weeks, ledipasvir–sofosbuvir+ribavirin for 8 weeks, ledipasvir–sofosbuvir for 12 weeks or ledipasvir–sofosbuvir+ribavirin for 12 weeks. In cohort 2, patients who had received sofosbuvir plus ribavirin for 12 or 24 weeks as part of a prior study (ClinicalTrials.gov, NCT01838590) but had failed to achieve SVR1215 or patients who had participated in cohort 1 of the current study and failed to achieve SVR12 with 8 weeks of ledipasvir–sofosbuvir+ribavirin were enrolled to receive ledipasvir–sofosbuvir+ribavirin for 12 weeks. Cohort 3 included interferon-experienced patients with no prior exposure to a direct-acting antiviral targeting HCV NS5A or NS5B polymerase. These patients were randomised in a 1:1 ratio to ledipasvir–sofosbuvir or ledipasvir–sofosbuvir+ribavirin for 12 weeks. Patients in cohorts 1 and 3 were stratified according to cirrhosis status.

Treatment
Ledipasvir–sofosbuvir was administered orally as a fixed-dose combination tablet (90 mg ledipasvir and 400 mg sofosbuvir), once daily. Ribavirin was administered twice daily, with food, at a total daily oral dose of 1000 or 1200 mg for patients weighing <75 kg or ≥75 kg, respectively. Dose reductions and discontinuation of ribavirin were allowed in accordance with the product label.

Endpoints
The primary efficacy endpoint was SVR12 (the proportion of patients with HCV RNA <LLOQ 12 weeks post-treatment). The primary safety endpoint was any adverse event leading to permanent discontinuation of study drug(s).

Study assessments
HCV RNA levels were determined using the Ampliprep/TaqMan HCV Test, V2.0 (Roche Molecular Systems, Branchburg, New Jersey, USA), which has a LLOQ of 15 IU/mL. Presence of cirrhosis was defined as liver biopsy with Metavir stage 4 or Ishak score of 5 or 6, a Fibroscan >12.5 kPa, or FibroTest score >0.75 and AST:platelet ratio index >2.

Safety assessments included clinical laboratory tests, physical examinations and vital signs measurements. Adverse events were monitored and documented throughout the study period. Although analyses of virological resistance were planned, samples collected for viral sequencing could not be analysed due to logistical obstacles.

Statistical analysis
Efficacy and safety were analysed in all randomised patients who received at least one dose of study drug. SVR12 was calculated for each treatment group using the exact binomial distribution with a two-sided 95% CI based on the Clopper-Pearson method. Other efficacy measurements were summarised using descriptive statistics. A sample size of at least 40 patients per treatment group in cohorts 1 and 3 was calculated to provide a two-sided 95% exact CI that would extend at most 32% in length, or 16% in either direction. The study was not powered to compare efficacy among treatment arms. Any patient with missing data due
Figure 1 Patient disposition. OT, on-treatment.

to premature discontinuation of the study drug was considered a failure at the date of discontinuation and all subsequent time points. If no HCV RNA values were obtained after the last dose of study medication, the patient was considered a treatment failure for the SVR endpoints.

Adverse events were coded using the Medical Dictionary for Regulatory Activities, V19.1. Safety data were analysed descriptively according to treatment received. All statistical summaries and analyses were performed using SAS software (V.9.4; SAS Institute, Cary, North Carolina, USA).

Study oversight

The study was approved by an independent ethics committee or institutional review board at all participating sites and was conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonization guidelines and complied with local laws and regulations. Written informed consent was obtained from all patients. All authors had access to the study data and approved the final version of the manuscript.

RESULTS

Patients

The study was conducted from 7 September 2015 to 11 November 2016 at four centres in Egypt. Of the 289 patients screened, 255 were enrolled and received at least one dose of study drug. The majority of patients not enrolled (33 of 34) did not meet eligibility criteria; one patient withdrew consent prior to enrolment (figure 1). In total, cohorts 1 and 3 enrolled 170 and 74 treatment-naive and interferon-experienced patients, respectively. Cohort 2 enrolled six patients from study NCT01838590 and five patients from cohort 1 of the current study. Only two patients (1%) discontinued study treatment prematurely; one had on-treatment virological failure at week 2 due to meeting the predefined stopping criteria of a confirmed >1 log increase in HCV RNA from on-treatment nadir and one discontinued due to an adverse event (car accident) at week 8.

Of the 255 patients in the study, 61% were men, 67% were treatment-naive, 21% had cirrhosis and 80% had IL28B non-CC genotype (table 1). Baseline characteristics were generally balanced across the treatment groups, except that the treatment-experienced cohorts (2 and 3) had a greater proportion of men (66%–89%) and patients with cirrhosis (26%–28%) compared with the treatment-naive groups (51%–58% and 16%–21%, respectively).

Efficacy

SVR12 rates are shown in figure 2. Among treatment-naive patients who received 8 weeks of treatment, the SVR rates were 95% (41/43; 95% CI 84% to 99%) without ribavirin and 90% (38/42; 95% CI 77% to 97%) with ribavirin (table 2). Notably, among the 71 treatment-naive patients without cirrhosis treated for 8 weeks, an overall SVR12 rate of 94% was observed (67/71; 95% CI 86% to 98%); 91% with ribavirin (32/35, CI 95% to 77% to 98%) and 97% without ribavirin (35/36, CI 95% 86 to 100%). Among the 71 patients without cirrhosis, 69 had a baseline HCV RNA <6 million IU/mL; among these patients, the same SVR rates by treatment were observed (94% overall, 91% and 97% with and without ribavirin, respectively).
Hepatology

Table 1  Baseline demographic and disease characteristics

| Cohort 1  | Treatment-naive | Cohort 2  | Ledipasvir/sofosbuvir or sofosbuvir-experienced | Cohort 3  | Interferon-experienced |
|-----------|-----------------|-----------|-----------------------------------------------|-----------|------------------------|
|           | Ledipasvir/sofosbuvir 8 weeks (n=43) | Ledipasvir/sofosbuvir+ribavirin 8 weeks (n=42) | Ledipasvir/sofosbuvir 12 weeks (n=43) | Ledipasvir/sofosbuvir+ribavirin 12 weeks (n=42) | Ledipasvir/sofosbuvir 12 weeks (n=36) | Ledipasvir/sofosbuvir+ribavirin 12 weeks (n=38) |
| Mean age, years (range) | 53 (22–74) | 49 (23–71) | 49 (23–74) | 46 (21–68) | 48 (23–72) | 49 (24–67) |
| Male, n (%) | 25 (58) | 22 (52) | 22 (51) | 22 (52) | 8 (73) | 32 (89) |
| Mean BMI, kg/m² (range) | 30.0 (22.0–50.0) | 31.4 (23.9–45.9) | 30.8 (21.0–45.7) | 29.5 (22.8–39.4) | 33.9 (23.6–50.8) | 29.1 (19.1–42.6) |
| Cirrhosis, n (%) | 7 (16) | 7 (17) | 9 (21) | 8 (19) | 3 (27) | 10 (28) |
| IL28B non-CC genotype, n (%) | 31 (72) | 37 (88) | 32 (74) | 33 (79) | 11 (100) | 31 (86) |

HCV RNA

| Mean, log₁₀ IU/mL (range) | 6.0 (4.7–7.0) | 5.6 (3.7–6.8) | 5.7 (4.3–7.0) | 5.8 (4.3–7.1) | 6.2 (5.2–7.0) | 5.8 (1.1–7.3) |
| ≥6 000 000 IU/mL, n (%) | 2 (5) | 0 | 2 (5) | 4 (10) | 3 (27) | 2 (6) |

Response to prior HCV treatment, n (%)

| Non-response | NA | NA | NA | NA | 0 | 18 (50) |
| Relapse/breakthrough | NA | NA | NA | NA | 11 (100) | 16 (44) |
| Interferon-intolerant | NA | NA | NA | NA | 0 | 2 (6) |

BMI, body mass index; HCV, hepatitis C virus; NA, not applicable.

The SVR rates among treatment-naive patients treated for 12 weeks was 98% with (41/42; 95% CI 87% to 100%) or without ribavirin (42/43; 95% CI 88% to 100%).

Among treatment-naive patients who did not achieve SVR12, six experienced post-treatment virological relapse, one patient had on-treatment virological failure and one patient early discontinued study treatment due to a serious adverse event of car accident. Of the six treatment-naive patients who relapsed, two patients received ledipasvir–sofosbuvir for 8 weeks, three received ledipasvir–sofosbuvir plus ribavirin for 8 weeks and one patient received ledipasvir–sofosbuvir plus ribavirin for 12 weeks. The five patients who relapsed after 8 weeks of treatment were enrolled into cohort 2 to receive ledipasvir–sofosbuvir plus ribavirin for 12 weeks. The patient with on-treatment virological failure had discontinued treatment at week 2 due to meeting the predefined stopping criteria of a confirmed >1 log increase in HCV RNA from on-treatment nadir (baseline HCV RNA was 4.95 log₁₀ IU/mL, week 1 was 2.42 log₁₀ IU/mL and week 2 was 4.75 log₁₀ IU/mL). This patient was non-cirrhotic with IL28B non-CC genotype TT and, according to pill count, was fully adherent to study drug for 23 days.

All 11 sofosbuvir or ledipasvir–sofosbuvir-experienced patients treated with ledipasvir–sofosbuvir plus ribavirin for 12 weeks achieved SVR12 (11/11; 95% CI 72% to 100%).

Among interferon-experienced patients treated for 12 weeks, the SVR rates were 94% (34/36; 95% CI 81% to 99%) without ribavirin and 100% (38/38; 95% CI 91% to 100%) with ribavirin. One patient experienced virological relapse after receiving 12 weeks of ledipasvir–sofosbuvir. One patient completed 12 weeks of ledipasvir–sofosbuvir and achieved SVR4, but died 84 days post-treatment; the cause of death is unknown.

Among treatment-naive or interferon-experienced patients, the addition of ribavirin did not substantially affect overall SVR12 rates (90%–100% with ribavirin and 94%–98% without ribavirin). In addition, among treatment-naive patients, SVR12 rates observed with 8 weeks of treatment (90%–95%) were similar to the SVR rates achieved with 12 weeks of treatment (98%) (table 3). In particular, 8 weeks of ledipasvir–sofosbuvir without ribavirin was highly effective in non-cirrhotic patients with an SVR12 of 97% (figure 3A). Cirrhosis status had no impact on observed SVR12 rates in interferon-experienced patients treated.
with ledipasvir–sofosbuvir for 12 weeks with or without riba-
vin (figure 3B). Other baseline characteristics including IL28B
 genotype, baseline HCV RNA and response to prior HCV treat-
ment had no impact on treatment outcome (table 3).

**Safety**
Adverse events and laboratory abnormalities by treatment
regimen are shown in table 4. In total, 37% of patients (16/43)
receiving ledipasvir–sofosbuvir for 8 weeks, 52% of patients
(22/42) receiving ledipasvir–sofosbuvir plus ribavirin for 8
weeks, 41% of patients (32/79) receiving ledipasvir–sofos-
 buvir for 12 weeks, and 63% of patients (57/91) receiving
ledipasvir–sofosbuvir plus ribavirin experienced at least one
treatment-emergent adverse event. The most common adverse
events were headache (occurring in 9%–31% of patients by
treatment regimen), fatigue (9%–15%) and anaemia (0%–8%).

**Table 2** Virological response following treatment

| Cohort 1 | Cohort 2 | Cohort 3 |
|----------|----------|----------|
| Treatment-naive | Ledipasvir/sofosbuvir or sofosbuvir-experienced | Interferon-experienced |
| Ledipasvir/sofosbuvir 8 weeks (n=43) | Ledipasvir/sofosbuvir 12 weeks (n=43) | Ledipasvir/sofosbuvir+ribavirin 12 weeks (n=11) |
| Ledipasvir/sofosbuvir+ribavirin 8 weeks (n=42) | Ledipasvir/sofosbuvir 12 weeks (n=42) | Ledipasvir/sofosbuvir+ribavirin 12 weeks (n=36) |
| HCV RNA<LOQ | SVR4 (95% CI) | SVR12 (95% CI) |
|-------------|-------------|-------------|
| 41 (95) (84 to 99) | 40 (95) (84 to 99) | 41 (98) (88 to 100) |
| 42 (98) (88 to 100) | 41 (98) (87 to 100) | 11 (100) (72 to 100) |
| 11 (100) (72 to 100) | 36 (100) (90 to 100) | 38 (100) (91 to 100) |

**Table 3** Subgroup analyses of SVR12 by baseline disease characteristics

| Baseline characteristic | Cohort 1 Treatment-naive | Cohort 2 Ledipasvir/sofosbuvir or sofosbuvir-experienced | Cohort 3 Interferon-experienced |
|-------------------------|--------------------------|--------------------------------------------------|--------------------------------|
| Cirrhosis, n (%) | | | |
| Yes | 6/7 (86) | 6/7 (86) | 10/10 (100) |
| No | 35/36 (97) | 32/35 (91) | 24/26 (92) |
| IL28B genotype, n (%) | | | |
| CC | 12/12 (100) | 5/5 (100) | 4/5 (80) |
| Non-CC | 29/31 (94) | 33/38 (89) | 30/31 (97) |
| Baseline HCV RNA | | | |
| <6 000 000 IU/mL, n (%) | 39/41 (95) | 38/42 (90) | 32/33 (97) |
| ≥6 000 000 IU/mL, n (%) | 2/2 (100) | 0/0 | 1/2 (50) |
| Response to prior HCV treatment, n (%) | | | |
| Non-responder | NA | NA | 18/18 (100) |
| Relapse/breakthrough | NA | NA | 14/16 (88) |
| Interferon-intolerant | NA | NA | 17/17 (100) |

HCV, hepatitis C virus; NA, not applicable; SVR12, sustained virological response at 12 weeks post-treatment.

*All values are n (%) unless stated otherwise. 10f the two patients with Other reason for failure, one patient from cohort 1 prematurely discontinued study treatment at day 56 due to a serious adverse event and one patient from cohort 3 died prior to study completion at 84 days post-treatment.
Overall, one patient discontinued treatment due to an adverse event. This patient, a treatment-naive 43-year-old man receiving ledipasvir–sofosbuvir plus ribavirin for 12 weeks, discontinued treatment on day 56 following a road traffic accident resulting in leg amputation. Serious adverse events were reported in three patients, all of whom were receiving ledipasvir–sofosbuvir plus ribavirin for 12 weeks. One patient, a 47-year-old man, suffered acute atypical chest pain of unknown aetiology on day 11 of treatment. Two patients were involved in road traffic accidents, one on day 17 and the other as mentioned above on day 56 resulting in leg amputation. None of the serious adverse events was considered treatment related. One 57-year-old male patient receiving ledipasvir–sofosbuvir died of unknown causes during the post-treatment period and was not considered related to study drug.

Twenty-seven patients had laboratory abnormalities (ledipasvir–sofosbuvir for 8 weeks, n=3; ledipasvir–sofosbuvir plus ribavirin for 8 weeks, n=3; ledipasvir–sofosbuvir for 12 weeks, n=6; ledipasvir–sofosbuvir plus ribavirin for 12 weeks, n=15) (table 4). Most laboratory abnormalities occurred only at one study visit. The most common abnormality was decreased haemoglobin levels 8.5 to <10 g/dL, all of which occurred in patients who received ribavirin (8 weeks, n=2; 12 weeks, n=7). One 57-year-old male patient receiving ledipasvir–sofosbuvir plus ribavirin for 12 weeks with a history of diabetes mellitus experienced hyperglycaemia.

Overall, the rates of adverse events were lower among patients receiving ribavirin-free treatment for 8 or 12 weeks (37% and 41%, respectively) than among those receiving ribavirin (52% and 63%, respectively) (table 4). The safety profile of the ribavirin-free regimens was similar regardless of treatment duration (37%–41%), whereas a greater proportion of patients in the ledipasvir–sofosbuvir plus ribavirin 12-week group had adverse events (63%) compared with the 8-week ribavirin-containing group (52%) (table 4). Of note, anaemia was observed only in patients who received ledipasvir–sofosbuvir plus ribavirin (7%) and no patients treated with ledipasvir–sofosbuvir alone.

**DISCUSSION**

This is the largest phase III trial evaluating a single tablet direct-acting antiviral regimen in patients with HCV genotype 4; it is also the largest such study in Egyptian patients. Given the high prevalence of HCV in Egypt and the heterogeneity of the HCV-infected population with respect to age, comorbidities and prior HCV therapy, there is a need in Egypt for a highly efficacious, well-tolerated, single-tablet regimen with simple monitoring. With the widespread use of sofosbuvir, an efficacious treatment for those who have failed treatment with a sofosbuvir-based regimen would also be highly desirable.

This study evaluated for the first time the safety and efficacy of ledipasvir–sofosbuvir for 8 weeks in patients with HCV genotype 4 infection. The shorter 8-week regimen of ledipasvir–sofosbuvir without ribavirin was highly effective in treatment-naive patients, with an overall SVR rate of 95%, and an even higher rate of 97% among not-cirrhotic patients, representing an option for this subgroup of patients. These results are comparable to those reported in the ION-3 study, where treatment-naive genotype 1 patients treated with 8 weeks of ledipasvir–sofosbuvir achieved SVR12 rates of 94% without ribavirin. Similar results were also observed with glecaprevir/pibrentasvir for 8 weeks that showed an SVR12 rate of 93% in HCV genotype 4 patients without cirrhosis. All other regimens evaluated in genotype 4 have been at least 12 weeks’ duration with or without ribavirin.17–30

Among interferon-experienced patients, treatment with ledipasvir–sofosbuvir without ribavirin for 12 weeks resulted in an SVR12 rate of 94%, which is comparable to that observed among genotype 1 patients in the ION-2 study.

In addition, this study demonstrated for the first time the safety and the high efficacy of ledipasvir–sofosbuvir plus ribavirin for 12 weeks in genotype 4 patients previously treated with sofosbuvir or ledipasvir/sofosbuvir, with an SVR12 of 100%. These results are in line with data previously reported in HCV genotype 1 patients who failed treatment with a sofosbuvir-based regimen and were retreated with ledipasvir–sofosbuvir plus ribavirin for 12 weeks.31

Although the addition of ribavirin did not appear to provide substantial benefit in terms of SVR rates for treatment-naive or interferon-experienced patients, it did lead to additional toxicity (patients with any AEs 52%–63% with ribavirin and 37%–41% without ribavirin).

**Figure 3** Proportion of treatment-naive patients (A) and treatment-experienced patients (B) achieving SVR12 according to cirrhosis status. Error bars represent 95% CIs. All patients who did not achieve SVR12 experienced virological relapse except: one treatment-naive patient who received LDV/SOF+RBV for 8 weeks (on-treatment virological failure), one treatment-naive patient who received LDV/SOF+RBV for 12 weeks (relapse after early discontinuation due to a serious adverse event) and one IFN-experienced patient who received LDV/SOF for 12 weeks (achieved SVR4, but died prior to post-treatment follow-up week 12). EXP, experienced; IFN, interferon; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virological response at 12 weeks post-treatment.
The limitations of our study include the relatively small number of some subgroup of patients such as patients with cirrhosis. However, this is the largest study published to date on the use of ledipasvir–sofosbuvir in genotype 4 patients. Additionally, the analysis of SVR according to baseline disease characteristics was exploratory. Therefore, the SVR rates observed in some baseline subgroups, such as the treatment-naive patients without cirrhosis, should be interpreted somewhat with caution due to relatively low patient numbers and lack of study power. Finally, sequencing analysis of the virological failures was not performed. As such, no interpretation of potential NSSA or NS5B resistance-associated substitutions can be made.

In summary, ledipasvir/sofosbuvir for 8 weeks was a highly effective treatment option for treatment-naive HCV genotype 4 patients without cirrhosis. Cirrhosis status did not affect the high SVR rates observed with ledipasvir/sofosbuvir for 12 weeks in interferon–experienced patients, and ledipasvir/sofosbuvir+ribavirin for 12 weeks was highly effective in patients previously treated with sofosbuvir+ribavirin or ledipasvir/sofosbuvir±ribavirin. The addition of ribavirin to the treatment regimen did not provide benefit in terms of overall SVR12 rates but did increase the incidence of adverse events.

### Table 4 Safety and adverse events by treatment regimen

| Event                      | Ledipasvir/sofosbuvir 8 weeks (n=43) | Ledipasvir/sofosbuvir + ribavirin 8 weeks (n=42) | Ledipasvir/sofosbuvir 12 weeks (n=79) | Ledipasvir/sofosbuvir+ribavirin 12 weeks (n=91) |
|----------------------------|--------------------------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|
| Any AE                     | 16 (37)                              | 22 (52)                                       | 33 (41)                            | 57 (63)                                     |
| Treatment-related AE       | 3 (7)                                | 10 (24)                                       | 11 (14)                            | 32 (35)                                     |
| Serious AE                 | 0                                    | 0                                             | 0                                  | 3 (3)                                       |
| Discontinuation of treatment owing to an AE | 0                                    | 0                                             | 0                                  | 1 (1)                                       |
| Death                      | 0                                    | 0                                             | 1 (1)†                              | 0                                           |
| Common AEs (occurring in >5% of patients receiving any treatment regimen) | | | | |
| Headache                   | 4 (9)                                | 13 (31)                                       | 12 (15)                            | 20 (22)                                     |
| Fatigue                    | 4 (9)                                | 5 (12)                                        | 8 (10)                             | 14 (15)                                     |
| Anaemia                    | 0                                    | 2 (5)                                         | 0                                  | 7 (8)                                       |
| Constipation               | 0                                    | 3 (7)                                         | 0                                  | 3 (3)                                       |
| Dyspepsia                  | 3 (7)                                | 1 (2)                                         | 5 (6)                              | 6 (7)                                       |
| Bronchitis                 | 3 (7)                                | 1 (2)                                         | 3 (4)                              | 2 (2)                                       |
| Abdominal pain             | 0                                    | 2 (5)                                         | 0                                  | 7 (6)                                       |
| Fever                      | 1 (2)                                | 1 (2)                                         | 1 (1)                              | 5 (5)                                       |
| Laboratory abnormalities   |                                      |                                               |                                    |                                             |
| Haemoglobin, 8.5 to <10 g/dL| 0                                    | 1 (2)                                         | 0                                  | 9 (10)                                      |
| Lipase, >5.0×ULN           | 1 (2)                                | 0                                             | 2 (3)                              | 1 (1)                                       |
| Hyperglycaemia, >250 to 500 mg/dL | 0                                    | 1 (2)                                         | 2 (3)                              | 1 (1)                                       |
| Hypernatraemia, >125 to <125 mEq/L | 0                                    | 1 (2)                                         | 0                                  | 1 (1)                                       |
| Neutrophils, 500 to <750/mm³ | 0                                    | 0                                             | 2 (3)                              | 0                                           |
| APTT, >3.00×ULN            | 1 (2)                                | 0                                             | 0                                  | 0                                           |
| INR, >2.0 to 3.0×ULN       | 1 (2)                                | 0                                             | 0                                  | 0                                           |
| Lymphocytes, 350 to <500/mm³ | 0                                    | 0                                             | 0                                  | 0                                           |
| Hyperkaemia, >6.5 to 7.0 mEq/L | 0                                    | 0                                             | 0                                  | 1 (1)                                       |
| Hyperbilirubinaemia, >2.5 to >5.0×ULN | 0                                    | 0                                             | 0                                  | 1 (1)                                       |
| White blood cells, 1.00 to <1.50 G/L | 0                                    | 0                                             | 0                                  | 0                                           |
| Platelets, 25 to <50 G/L   | 0                                    | 0                                             | 0                                  | 0                                           |

*All values are n(%) unless stated otherwise.
†Cause of death unknown.

AE, adverse event; APTT, active partial thromboplastin time; INR, international normalised ratio of prothrombin time; ULN, upper limit of normal.

**Correction notice** This article has been corrected since it published Online First. Table 1 and affiliation 3 have been updated.

**Contributors** All authors had access to the data and approved the final version of the manuscript.

**Funding** This study was funded by Gilead Sciences Inc. (Foster City, California, USA).

**Competing interests** GS has served as a principal investigator for AbbVie and Gilead. GE has served as a principal investigator for AbbVie, Gilead, BMS and Pharco Pharmaceuticals, and has served as a speaker for Gilead and BMS, and has served on advisory boards for Gilead and MSD. MH has served as an investigator for AbbVie, Janssen and Gilead, and has served as a speaker for AbbVie and Pharco. RS has served as an investigator for AbbVie and Gilead. ME has served as an investigator for Gilead. RF has served as an investigator for Gilead, Abbie and Pharco Pharmaceuticals. AE has served as an investigator for Gilead, Abbvie and Janssen. RH declare no conflicts of interest. WA-R has served as a co-investigator for Gilead, Janssen and Abbvie. TZ has served as a co-investigator for Janssen and Abbvie. IW has served as an investigator, speaker and on advisory boards for Abbvie, Eva Pharma, Gilead, Janssen, Marcyrl, Onxio, Pharco and Rocho. WD has served as an investigator for Abbvie, Janssen and Gilead. The following coauthors are employees of and hold stock interest in Gilead Sciences: KK, BM, AO, SL, DMB and JGMCh.

**Patient consent** Obtained.

**Ethics approval** The protocol was approved by an independent ethics committee or an institutional review board according to site-specific regulations.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** All authors had access to the data.
REFERENCES

1. Gomaa A, Alami N, Elsharkawy A, et al. Hepatitis C virus infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017;9:17–25.

2. Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], and ICF International. Egypt health issues survey 2015. Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International, 2015.

3. Miller FD, Abu-Raddad LI. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010;107:14757–62.

4. Razavi H, Waked I, Sarrar C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21 Suppl 1(Suppl 1):34–59.

5. Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014;15:45–52.

6. Gower E, Esles C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):545–557.

7. Elsharkawy A, Fouda R, El Akel W, et al. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther 2017;45:681–7.

8. Kadmon Pharmaceuticals LLC. Ribashphere (ribavirin, USP) tablets for oral use. US Prescribing Information. 2014 https://kadmon.com/files/ribashphere-tablets-pi.pdf (accessed 9 Nov 2017).

9. Roche Products Limited. Cop egus (ribavirin) tablets for oral use. Summary of Product Characteristics. 2015 http://www.medicines.org.uk/emc/print-document?documentId=19416 (accessed 09 Nov 2017).

10. Althal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93.

11. Althal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–98.

12. Kowdle FY, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88.

13. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015;15:1049–54.

14. Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016;64:1049–56.

15. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015;63:581–5.

16. Asselah T, Kowdle KV, Zadekis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018;16:417–26.

17. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017;67:263–71.

18. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 in infection in patients with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062–8.

19. Poordad F, Pol S, Asatryan A, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2017 [Epub ahead of print 20 Nov 2017].

20. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385:2502–9.

21. Asselah T, Hézode C, Qasim RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:25–35.

22. Waked I, Shiha G, Qasim RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-III): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:36–44.

23. Poordad F, Schirrf ER, Vierling JM, et al. Daclatasvir and sofosbuvir with ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493–505.

24. Wyles D, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714–25.

25. Buti M, Calleja IL, Lens S, et al. Simeprevir in combination with sofosbuvir in treatment-naive and -experienced patients with hepatitis C virus genotype 4 infection: a phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 2015;45:468–75.

26. El Raziky M, Gamal M, Ashour MK, et al. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. J Viral Hepat 2017;24:102–10.

27. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599–607.

28. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–28.

29. Zeuzem S, Chalili R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1–13.

30. Brown A, Hézode C, Zuckerman E, et al. Efficacy and safety of 12 weeks of elbasvir + grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: the C-SCAPE study. J Viral Hepat 2017. [Epub ahead of print].

31. Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimen. Hepatology 2015;61:1793–7.